Zanamivir
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | <applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Zanamivir, better known as Relenza, ([[ | + | <applet load="" size="480" color="" frame="true" spin="on" Scene ="Zanamivir/Zanamivir/1" align="right" caption="Zanamivir, better known as Relenza, ([[3b7e]])"/> |
===Better Known as: Relenza=== | ===Better Known as: Relenza=== | ||
* Marketed By: GlaxoSmithKline | * Marketed By: GlaxoSmithKline | ||
Revision as of 11:51, 12 December 2010
|
Better Known as: Relenza
- Marketed By: GlaxoSmithKline
- Major Indication: Influenza Infection
- Drug Class: Neuraminidase Inhibitor
- Date of FDA Approval (Patent Expiration): 1999 (2016)
- 2009 Sales:$1.1 Billion
- Importance: It was the first neuraminidase inhibitor to be approved by the FDA, followed a few months later by Oseltamivir. Newer strains of flu virus, primarily H1N1, have developed varying levels of resistance to Oseltamivir, but a lesser extent to Zanamivir. Sales have increased dramatically since 2006 with scares of bird flu and swine flu pandemics.
- See Pharmaceutical Drugs for more information about other drugs and diseases.
Mechanism of Action
Pharmacokinetics
For References to Pharmacokinetic data, see: References |
||||||||||||||||||||||||||||||||||||||||||
References
